Maria Stella Pennisi
Overview
Explore the profile of Maria Stella Pennisi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
538
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Massimino M, Stella S, Tirro E, Pennisi M, Stagno F, Vitale S, et al.
Onco Targets Ther
. 2023 Oct;
16:803-816.
PMID: 37807980
Purpose: Chronic Myeloid Leukemia (CML) is a clonal disorder of the hematopoietic stem cell caused by expression of the oncoprotein. High levels have been associated to proliferative advantage of leukemic...
2.
Pennisi M, Di Gregorio S, Tirro E, Romano C, Duminuco A, Garibaldi B, et al.
Hematol Rep
. 2023 Jun;
15(2):317-324.
PMID: 37367082
Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are two of the main -negative chronic myeloproliferative neoplasms (MPNs) characterized by abnormal megakaryocytic proliferation. () mutations are detected in 50-60% of ET...
3.
Romano C, Di Gregorio S, Pennisi M, Tirro E, Broggi G, Caltabiano R, et al.
Mol Biol Rep
. 2022 Jun;
49(9):9059-9064.
PMID: 35715605
Background: Multiple primary malignancies (MPM) are defined as tumors originating in the same individual without any correlation between them. In addition to morphological and immunohistochemical analyses, sensitive DNA sequencing methods...
4.
Stella S, Vitale S, Stagno F, Massimino M, Puma A, Tomarchio C, et al.
Diagnostics (Basel)
. 2022 May;
12(5).
PMID: 35626209
Background: Detection of transcript level via real-time quantitative-polymerase-chain reaction (Q-PCR) is a clinical routine for disease monitoring, assessing Tyrosine Kinase Inhibitor therapy efficacy and predicting long-term response in chronic myeloid...
5.
Massimino M, Vigneri P, Stella S, Tirro E, Pennisi M, Parrinello L, et al.
J Clin Med
. 2021 Dec;
10(23).
PMID: 34884309
Background: The management of Philadelphia Chromosome-positive (Ph+) hematological malignancies is strictly correlated to the use of BCR-ABL1 tyrosine kinase inhibitors (TKIs). However, these drugs do not induce leukemic stem cells...
6.
Stella S, Vitale S, Massimino M, Puma A, Tomarchio C, Pennisi M, et al.
Diagnostics (Basel)
. 2021 Aug;
11(8).
PMID: 34441436
Molecular testing of the transcript via real-time quantitative-polymerase-chain-reaction is the most sensitive approach for monitoring the response to tyrosine-kinase-inhibitors therapy in chronic myeloid leukaemia (CML) patients. Each stage of the...
7.
Romano C, Martorana F, Pennisi M, Stella S, Massimino M, Tirro E, et al.
Int J Mol Sci
. 2021 Jul;
22(14).
PMID: 34299334
Thyroid cancer is the most common malignancy of the endocrine system, encompassing different entities with distinct histological features and clinical behavior. The diagnostic definition, therapeutic approach, and follow-up of thyroid...
8.
Massimino M, Tirro E, Stella S, Manzella L, Pennisi M, Romano C, et al.
Front Pharmacol
. 2021 Jul;
12:669469.
PMID: 34276365
Chronic Myeloid Leukemia (CML) is a hematological disorder characterized by the clonal expansion of a hematopoietic stem cell carrying the Philadelphia chromosome that juxtaposes the and genes. The ensuing chimeric...
9.
Tirro E, Massimino M, Romano C, Martorana F, Pennisi M, Stella S, et al.
Front Oncol
. 2021 Feb;
10:612385.
PMID: 33604294
Glioblastoma multiforme (GBM) is the most common primary brain malignancy and is often resistant to conventional treatments due to its extensive cellular heterogeneity. Thus, the overall survival of GBM patients...
10.
Stella S, Massimino M, Manzella L, Pennisi M, Tirro E, Romano C, et al.
Int J Mol Sci
. 2021 Jan;
22(2).
PMID: 33418988
Hypereosinophilia (HE) is a heterogeneous condition with a persistent elevated eosinophil count of >350/mm, which is reported in various (inflammatory, allergic, infectious, or neoplastic) diseases with distinct pathophysiological pathways. HE...